



GENERAL PROGRAMME PROVISIONAL

last update: 27 July 2022

CET time zone

DAY 1 (23 November)

08.00-09.00	Registration and welcome coffee	
09.00-10.00	Plenary session A Controlling a pandemic – what are the ethical boundaries? <i>Chaired by Andrea Ammon (ECDC) and ESCAIDE Scientific Committee member Mike Catchpole (ECDC)</i> Keynote speaker: Alena Buyx	
10.00-10.30	Message from ECDC Director and ECDC Chief Scientist	
10.30-11.00	Coffee break	
11.00-12.30	Fireside session 1 Implementation science	Fireside session 2 HIV, sexually transmitted and community infection
12.30-14.30	Lunch break	12.30–13.00 <i>Yoga and body stretching</i> 13.00–13.30 Online only-posters 13.00–14.00 <i>Session TBC</i>
13.30-15.00	13.30-15.00 Fireside session 3 Secondary public health impacts	14.00–15.00 <i>Session TBC</i>
15.15-16.00	Poster tour 1 Knowledge for policy and practice Poster tour 2 Emerging and vector-borne diseases Poster tour 3 Respiratory diseases Poster tour 4 Food -and water borne diseases and zoonoses	
16.00-16.30	Coffee break	
16.30-18.00	Plenary session B Refugees and refuge: how to promote and protect the health of displaced people <i>Chaired by the ESCAIDE Scientific Committee members Stine Nielsen (EAN) and Chikwe Ihekweazu (WHO)</i> Speakers: Paul Spiegel (Johns Hopkins Center), Aurélie Ponthieu (Médecins Sans Frontières), Grzegorz Juszczak (National Institute of Health, Poland), Apostolos Veizis (INTERSOS, Greece)	
18.00-18.15	Daily wrap-up	
18.30-20.30	Networking cocktail	

NOTES *This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.*



GENERAL PROGRAMME PROVISIONAL

CET time zone

DAY 2 (24 November)

08.30-09.00	Welcome coffee		
	Plenary session C		
09.00-10.30	Revolutions in vaccination in the age of COVID-19 <i>Chaired by the ESCAIDE Scientific Committee members John Kinsman (ECDC) and Magdalena Rosińska (NIPH-NIH, Poland)</i> Speakers: Hanna Nohynek (THL), Cornelia Betsch (University of Erfurt, Germany), Jeremy Ward (INSERM, France)		
10.30-11.00	Coffee break		
11.00-12.30	Fireside session 4 COVID-19: vaccine effectiveness	Fireside session 5 COVID-19: surveillance action	
12.30-14.30	Lunch break	12.30-13.00 <i>Yoga and body stretching</i>	12.30-14.00 EAN General Assembly meeting (closed event)
		13.00-13.30 Online only-posters	
13.30-15.00	13.30-15.00 <i>Eurosurveillance Seminar</i> Communicating science: social media and other means <i>Pitfalls and benefits</i>	14.00-15.00 MediPIET event	
15.15-16.00	Poster tour 5 COVID-19: vaccination and immunity and health promotion Poster tour 6 Intervention and health promotion Poster tour 7 Antimicrobial resistance Poster tour 8 Surveillance: opportunities and evaluation Poster tour 9 Late-breakers		
16.00-16.30	Coffee break		
16.30-18.00	Plenary session D Cutting through the noise: the role of Public Health experts in managing an infodemic <i>Chaired by the ESCAIDE Scientific Committee members Adam Roth (ECDC), Petronille Bogaert (Sciensano, Belgium), and Mircea Ioan Popa (Carol Davila University of Medicine and Pharmacy, Romania)</i> Speakers: Mihai Craiu (Mother and Children Hospital, Bucharest), Neville Calleja (Ministry for Health, Malta), Alma Tostmann (Radboudumc, Netherlands), Martyna Bildziukiewicz (European External Action Service)		
18.00-18.15	Daily wrap-up		
18.30-20.00	BarCamp		

NOTES *This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.*



GENERAL PROGRAMME *PROVISIONAL*

CET time zone

DAY 3 (25 November)

08.30-09.00	Welcome coffee	
09.00-10.30	Plenary session E The COVID-19 pandemic – a surveillance game changer? <i>Chaired by the ESCAIDE Scientific Committee members Vicky Lefevre (ECDC), Bruno Coignard (Santé publique France), and Luísa Peixe (University of Porto)</i> Speakers: Silke Buda (RKI, Germany), Søren Alexandersen (SSI, Denmark), Fernando Simon (Ministry of Health, Spain)	
10.30-11.00	Coffee break	
11.00-12.30	Fireside session 6 COVID-19: intervention and health promotion	Fireside session 7 Food -and water borne and vector diseases
12.30-14.30	Lunch	12.30–13.00 <i>Yoga and body stretching</i> 13.00–13.30 Online only-posters 14.00–15.00 Career Compass
13.30-15.00	Fireside session 8 COVID-19: Surveillance approaches	Fireside session 9 Late breakers
15.15-16.00	Poster tour 10 Surveillance approaches Poster tour 11 Food -and water borne diseases and zoonoses: outbreaks Poster tour 12 Antimicrobial resistance Poster tour 13 COVID-19: vaccine effectiveness	
16.00-16.30	Coffee break	
16.30-17.00	Final wrap-up	
17.00-17.30	Closing ceremony and awards	

NOTES This is a provisional programme and sessions may change. The final programme will be published closer to the conference dates.



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

CET time zone

DAY 1 (23 November)

<p>11.00-12.30</p>	<p>Fireside session 1 moderated by Implementation science</p> <ul style="list-style-type: none"> a. Community-based One Health Approach to Prevent, Detect and Respond to Disease Outbreaks, <i>Muhammad Abdi Haryono</i> b. Collaborative modelling of the future dynamics of COVID-19: the European Forecasting and Scenario Hubs, <i>Katharine Sherratt</i> c. Endemic Zika Virus in Brazil, <i>Laith Yakob</i> d. Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan <i>Dilyara Nabirova</i> e. An Approach to Developing One Health Field Epidemiology Competencies, <i>Marion Muehlen</i> f. Enhanced event-based surveillance: monitoring events during the Ukraine crisis, 2022, <i>Jon Bilbatua</i> 	<p>Fireside session 2 moderated by HIV, sexually transmitted and community infection</p> <ul style="list-style-type: none"> a. Invasive beta-hemolytic streptococcal infections in Finland, 2006-2020: The rise of Lancefield group C/G infections, <i>Dafni Katerina Paspaliari</i> b. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland, <i>Jin-Min Yuan</i> c. Neisseria gonorrhoeae antimicrobial resistance surveillance in the Netherlands: a 10-year overview, <i>Maartje Visser</i> d. Contribution of Sexual Health Centres in hepatitis B detection and control in the Netherlands, <i>Stijn Raven</i> e. Effects of Improving Partner Notification on HIV and gonorrhoea transmission among men who have sex with men in the Netherlands, <i>Maarten Reitsema</i> f. The impact of the COVID-19 pandemic on the transmission of hepatitis B virus among men who have sex with men: a mathematical modelling study, <i>Maria Xiridou</i>
<p>13.30-15.00</p>	<p>Fireside session 3 moderated by Secondary public health impacts</p> <ul style="list-style-type: none"> a. How COVID-19 fast-tracked the development of a national microbiology laboratory database for surveillance in Norway: Success factors, <i>Nina Aasand</i> b. Impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB cases in Ireland, 2011-2021, <i>Sarah Jackson</i> c. A systematic review on the impact of COVID-19 on cervical cancer prevention, diagnosis and treatment, <i>Giulia Dallagiacoma</i> d. The impact of the COVID-19 pandemic and non-pharmaceutical interventions on infectious diseases under national surveillance in the Netherlands from 2020 to Q1 2022, <i>Denise Van Hout</i> 	<p style="text-align: center;"><i>Session TBC</i></p>



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

CET time zone

DAY 2 (24 November)

<p>11.00-12.30</p>	<p>Fireside session 4 moderated by TBC</p> <p>COVID-19: vaccine effectiveness</p> <ul style="list-style-type: none"> a. Vaccine effectiveness against COVID-19 and associated death in Alpha and Delta variant outbreaks in long-term care facilities in Germany, <i>Mirco Sandfort</i> b. Primary course and booster vaccine effectiveness against Omicron: Results from a European multicentre study at primary care/ambulatory level, <i>Esther Kissling</i> c. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period in the Netherlands: A nationwide study adjusting for chance of exposure, <i>Katja van Ewijk</i> d. Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study, <i>Tobias Homan</i> e. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged 65+ years using electronic health registries; pilot study in four EU/EEA countries, January-February 2022, <i>Alexis Sentis Fuster</i> f. A new challenge for control selection in influenza vaccine effectiveness test-negative design studies in the COVID-19 context: Results from the European I-MOVE multicentre study at primary care level, <i>Esther Kissling</i> 	<p>Fireside session 5 moderated by TBC</p> <p>COVID-19: surveillance action</p> <ul style="list-style-type: none"> a. Comparative risk of cerebral venous sinus thrombosis (CVST) following SARS-CoV-2 vaccination or infection: A national cohort study using linked electronic health records, <i>Columbus Ohaeri</i> b. Risk of SARS-CoV-2 infection among members of a fitness centre chain in Stockholm, Sweden 2020: Is going to the gym risky?, <i>Anine Kongelf</i> c. Bus riding as amplification mechanism for an explosive COVID-19 outbreak after import of SARS-CoV-2 by air travellers, Germany, 2021, <i>Meike Schöll</i> d. Disease severity and outcomes of COVID-19 in cases infected with SARS-CoV-2 Delta and Omicron variants, Skåne region, Sweden, December 2021 - January 2022, <i>Anine Kongelf</i> e. A comparison of COVID-19 critical care admission incidence in Wales by vaccine status, <i>Mai Barry</i> f. Estimate of school-specific reproductive number during weekly screening in the Auvergne-Rhône-Alpes region, France, week 47 to 50, 2021, <i>Elisabetta Colosi</i>
---------------------------	---	---



FIRESIDE SESSIONS PROGRAMME *PROVISIONAL*

CET time zone

DAY 3 (25 November)

<p>11.00-12.30</p>	<p>Fireside session 6 moderated by TBC</p> <p>COVID-19: intervention and health promotion</p> <ul style="list-style-type: none"> a. Nosocomial acquisition not associated with increased mortality amongst hospitalised COVID-19 cases in Wales, Feb 2020-Mar 2022, <i>Rubeshkumar Polani</i> b. Determinants of healthcare workers' self-reported compliance to infection prevention and control during the COVID-19 pandemic: a cross-sectional study in Dutch residential care facilities for people with intellectual and developmental disabilities, <i>Famke Houben</i> c. Incidence rate and risk factors associated with SARS-CoV-2 infection in healthcare workers from three European hospitals, July 2021-April 2022, <i>Camelia Savulescu</i> d. Assessing the robustness of SARS-CoV-2 vaccine trial results: systematic review and meta-analysis, <i>Ngoc-Anh Hoang</i> e. Socioeconomic patterns of COVID-19 vaccine uptake in children aged 5-11 in Italy (January - April 2022), <i>Alberto Mateo Urdiales</i> f. The association between SARS-CoV-2 seroprevalence and cross-border mobility for visiting family or friends among Dutch residents of a border province, <i>Demi ME Pagen</i> 	<p>Fireside session 7 moderated by TBC</p> <p>Food -and water borne and vector diseases</p> <ul style="list-style-type: none"> a. Regional shift in Pogosta disease incidence during 2021 epidemic in Finland, <i>Eveline Otte im Kampe</i> b. Risk of lymphoma increased after Puumala virus infection in Finland, 2009-2019: a retrospective register-based study, <i>Sohvi Kääriäinen</i> c. An Easter Surprise: Salmonella Typhimurium outbreak linked to chocolate products in the United Kingdom, 2022; a case control study, <i>Amoolya Vusirikala</i> d. International outbreak of Salmonella Typhimurium linked to a chocolate factory in 2022: Belgian findings, <i>Valeska Laisnez</i> e. Whole Genome Sequencing identified a prolonged Salmonella Poona nursery outbreak (2016-2021) in North West England, UK, <i>Joanna Garner</i> f. Climate Warming and increasing Vibrio vulnificus infections in North America, <i>Elizabeth Archer</i>
<p>13.30-15.00</p>	<p>Fireside session 8 moderated by TBC</p> <p>COVID-19: Surveillance approaches</p> <ul style="list-style-type: none"> a. Linkage of SARS-CoV-2 sequencing results to the Bavarian surveillance system from January 2021 through February 2022, Germany, <i>Liza Coyer</i> b. Using a novel 'difference-in-differences' method and syndromic surveillance to estimate the impact of media reporting on local healthcare utilisation during an early stage of the COVID-19 pandemic, <i>Aryan Nikhab</i> c. Wastewater surveillance for SARS-CoV-2 closely mirrors incidence data: results from national surveillance in Denmark, October 2021 - May 2022, <i>Oliver McManus</i> d. SARS-CoV-2 Genomic Surveillance: Lessons Learned from the EMERGEN Consortium, France, 2021-2022, <i>Justine Schaeffer</i> e. How do we keep a cohort engaged? Lessons from one year of following up over 44,000 SIREN study participants, UK, <i>Anna Howells</i> 	<p>Fireside session 9 moderated by TBC</p> <p>Late breakers</p> <p>TBC</p>



POSTER TOURS PROGRAMME *PROVISIONAL*

CET time zone

DAY 1 (23 November)

15.15-16.00	<p>Poster tour 1 moderated by TBC</p> <p>Knowledge for policy and practice</p> <ul style="list-style-type: none"> a. The COVID-19 pandemic impacted syphilis testing at anonymous consultation clinics in North-Rhine Westphalia state, Germany, 2019-2021, <i>Katja Siling</i> b. Translating the COVID-19 epidemiological situation into policies and measures: the Belgian experience, <i>Geraldine De Muylder</i> c. One Health in policy and practice: A UK case study of <i>Corynebacterium ulcerans</i> in a pet and challenges managing human health risk for zoonotic disease where guidance is focused on human cases, <i>Penelope Cresswell-Jones</i> d. Importance of regional networking in building national FETP: Experience of Lebanon, <i>Zeina Farah</i> e. Assessment of infection prevention and control in hospitals providing medical care for coronavirus infection (COVID-19) in Bishkek, Osh cities and Chui region, Kyrgyzstan, 2020, <i>Altynai Dzhalmbekova</i> f. Activation of crisis management structures at the Robert Koch Institute during the COVID-19 pandemic, <i>Ulrike Grote</i>
15.15-16.00	<p>Poster tour 2 moderated by TBC</p> <p>Emerging and vector-borne diseases</p> <ul style="list-style-type: none"> a. Modelling the human force of infection of West Nile virus in Europe, <i>Giovanni Marini</i> b. Risk assessment and preparedness plan development for West Nile Virus (WNV) transmission in the State of Baden-Wuerttemberg, Germany, 2022, <i>Sabrina Nothdurfter</i> c. Predictors of Lassa fever diagnosis in suspected cases reporting in health facilities: A secondary data analysis of Nigerian surveillance data, 2018-2021, <i>Sandra Mba</i> d. Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012-2020, <i>Jasper Van Heuverswyn</i> e. Modelling Elevated tick borne encephalitis seroprevalence in blood donors in regions classified as moderately-affected or low -risk in Poland, 2022, <i>Katarzyna Pancer</i>
15.15-16.00	<p>Poster tour 3 moderated by TBC</p> <p>Respiratory diseases</p> <ul style="list-style-type: none"> a. Integrated surveillance of SARS-CoV-2 and other human respiratory viruses in a public testing facility in Utrecht, the Netherlands to monitor co-circulation in a susceptible population, <i>Stijn Raven</i> b. Feasibility to estimate real-time influenza vaccine effectiveness: a pilot study across five European study sites, <i>Marine Maurel</i> c. The epidemiology of respiratory syncytial virus in children during the COVID-19 pandemic measured by laboratory, clinical and syndromic surveillance in England: a retrospective observational study, <i>Megan Bardsley</i> d. Differences found in the epidemiology of Tuberculosis (TB) among migrants versus non-migrants in Ireland, 2011-2020, <i>Sarah Jackson</i> e. A SARS-CoV-2 Omicron outbreak among crew members on a cruise ship in Germany in early 2022, <i>Silja Bühler</i> f. COVID-19 outbreak in an elderly care home: very low vaccine effectiveness and late impact of booster vaccination campaign, <i>Katja van Ewijk</i>
15.15-16.00	<p>Poster tour 4 moderated by TBC</p> <p>Food -and water borne diseases and zoonoses</p> <ul style="list-style-type: none"> a. Timely and reliable outbreak investigation using a non-probabilistic online panel as a source of controls - two parallel case-control studies investigating a Salmonella Braenderup outbreak in Germany, <i>Anna Luczynska</i> b. An outbreak of Escherichia coli-associated haemolytic uremic syndrome linked to consumption of an unexpected food vehicle, France 2022, <i>Catarina Krug</i> c. Outbreak investigation of cholera in a peri-urban village of Panchkula district, Haryana, India, 2021, <i>Shivani Gupta</i> d. Cholera Outbreak Investigation, Ballo Adda Mohalla, Lucknow District, Uttar Pradesh 2021, <i>Surabhi Tripathi</i> e. Norovirus GII.3[P12] outbreak associated with the drinking-water supply in a rural area in Galicia, Spain, 2021, <i>Camille Jacqueline</i>



POSTER TOURS PROGRAMME *PROVISIONAL*

CET time zone

DAY 2 (24 November)

11.30-12.00	<p>Poster tour 5 moderated by TBC</p> <p>COVID-19: vaccination and immunity</p> <ul style="list-style-type: none"> a. Seroprevalence of SARS-CoV-2 IgG antibodies and factors associated with neutralizing activity among primary health care workers six months after vaccination rollout in France, <i>Marie Pouquet</i> b. Early vaccination of day-care staff significantly reduced SARS-CoV-2 transmission in day-care centers in Rhineland-Palatinate, Germany, in 2021, <i>Anja Schoeps</i> c. Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long term care facility residents, <i>Dorothee Obach</i> d. The effect of hybrid immunity during Omicron variant wave in a European healthcare worker cohort, December 2021 - April 2022, <i>Camelia Savulescu</i> e. B cell mediated immunogenicity following boosting with the BNT162b2 SARS-CoV-2 vaccine in dialysis patients, Israel, 2021-22, <i>Neta Tuvia</i> f. Estimating COVID-19 and influenza vaccination coverage in homeless populations; Wales, UK, <i>Gethin Jones</i>
11.30-12.00	<p>Poster tour 6 moderated by TBC</p> <p>Intervention and health promotion</p> <ul style="list-style-type: none"> a. Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a vaccine-hesitant religious group, <i>Anne de Munter</i> b. Advocacy and community engagement in TB control: the Kano wellness on wheels (WoW) experience, <i>Mustapha Musa Tukur</i> c. Hantavirus and Leptospira spp.: Seroprevalence, knowledge and preventive behaviour in seasonal harvesters in Lower Saxony, Germany, 2021, <i>Saskia Schmitz</i> d. Considerable doubt about rubella screening and vaccination intention among unvaccinated orthodox Protestant women, <i>Anne de Munter</i> e. Lessons from a protracted iGAS outbreak with added complexity of concurrent scabies outbreak, in a UK residential nursing care facility 2020-2021, <i>Philippa Williams</i> f. Vaccine confidence among the adult population of Bishkek and Naryn, Kyrgyz Republic, 2021, <i>Marina Malisheva</i>
11.30-12.00	<p>Poster tour 7 moderated by TBC</p> <p>Antimicrobial resistance</p> <ul style="list-style-type: none"> a. Emergence of carbapenemase-producing <i>Enterobacterales</i> causing infection in companion animals, <i>Joana Moreira Da Silva</i> b. Trends in antibiotic resistance in Portugal: analysis of surveillance data from 2015 to 2020, <i>Vera Manageiro</i> c. Increasing trends in extended-spectrum β-lactamase production in urine and blood <i>Escherichia coli</i> isolates in Finland in 2008-2019: a retrospective nationwide study, <i>Heikki Ilmavirta</i> d. Increase in extensively-drug resistant <i>Shigella sonnei</i> infections in Spain, 2021-2022, <i>Camille Jacqueline</i> e. Failure of scabies treatment: a systematic review and meta-analysis, <i>Felix Reichert</i> f. International patient transfers causing healthcare associated outbreaks of carbapenem-resistant <i>Acinetobacter baumannii</i> in Germany, August - September 2021, <i>Jonatha Baum</i>
11.30-12.00	<p>Poster tour 8 moderated by TBC</p> <p>Surveillance: opportunities and evaluation</p> <ul style="list-style-type: none"> a. <i>Candida auris</i> in Attica hospitals, Greece: yet another Hospital Acquired Infection, <i>Lida Politi</i> b. <i>Clostridioides difficile</i> infection surveillance system in Norway: evaluation of the data completeness, 2019-2021, <i>Lea Franconeri</i> c. Wastewater-based surveillance of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Finland: Informed selection of sites for sampling, <i>Dafni Katerin Paspaliari</i> d. Evaluation of random-digit-dialing (RDD) recruitment to invite participants for serological tests as a method to obtain a representative sample for general population seroepidemiological surveys, <i>Magdalena Rosinska</i> e. Evaluation of 17 years of MERIN (Meningitis and Encephalitis register in Lower Saxony, Germany) surveillance program: acceptability survey and data quality assessment, <i>Anna Luczynska</i> f. Evaluation and comparison of statistical algorithms for monitoring COVID-19 case and death trends in EU/EEA Member States, <i>Joana Gomes Dias</i>
11.30-12.00	<p>Poster tour 9 moderated by TBC</p> <p>Late breakers</p> <p>TBC (after conclusion of late breakers abstracts process)</p>



POSTER TOURS PROGRAMME *PROVISIONAL*

CET time zone

DAY 3 (25 November)

11.30-12.00	<p>Poster tour 10 moderated by TBC</p> <p>Surveillance approaches</p> <ul style="list-style-type: none"> a. SARS-CoV-2 in schoolchildren during the Delta variant wave August to December 2021– finding from the Danish comprehensive register-based surveillance system, <i>Tjede Funk</i> b. Rapid establishment of a prospective surveillance system for child mortality and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England, <i>Gemma Smith</i> c. Repeated nationwide serosurveillance of SARS-CoV-2 in the Netherlands during the second year of the pandemic: a prospective population-based cohort, <i>Eric Vos</i> d. Investigating opportunities for surveillance of long term chlamydia complications in the Netherlands: a qualitative study, <i>Elke Den Boogert</i> e. Characterisation of measles transmission chains in three outbreaks in the post-elimination phase. Spain 2017-2019, <i>Kevin Bliet-Bueno</i> f. Evaluating severity parameters for scaling up and down public health and social measures during the COVID-19 pandemic in select WHO Member States, <i>Holly Sadler</i>
11.30-12.00	<p>Poster tour 11 moderated by TBC</p> <p>Food -and water borne diseases and zoonoses: outbreaks</p> <ul style="list-style-type: none"> a. Monophasic <i>Salmonella Typhimurium</i> outbreak linked to chocolate products, Ireland, 2022, <i>Charlotte Salgaard Nielsen</i> b. Successful containment of a <i>Listeria monocytogenes</i> outbreak caused by shredded vegetables, Hesse/Germany, 2021-2022, <i>Laura Becker</i> c. Outbreak of monophasic <i>Salmonella Typhimurium</i> linked to fresh small tomatoes, Sweden, 2021, <i>Karolina Fischerström</i> d. Cluster of dog bite injuries and rabies exposures - Tajikistan, 2022, <i>Rajabali Sharifov</i> e. High fatality rate from probable botulism linked to home canning - Tajikistan, 2021, <i>Sakina Shoeva</i> f. Lassa fever in the East of England: the multiagency response, <i>Eleanor Turner-Moss</i>
11.30-12.00	<p>Poster tour 12 moderated by TBC</p> <p>Antimicrobial resistance</p> <ul style="list-style-type: none"> a. Emergence of carbapenemase-producing <i>Enterobacterales</i> causing infection in companion animals, <i>Joana Moreira Da Silva</i> b. Trends in antibiotic resistance in Portugal: analysis of surveillance data from 2015 to 2020, <i>Vera Manageiro</i> c. Increasing trends in extended-spectrum β-lactamase production in urine and blood <i>Escherichia coli</i> isolates in Finland in 2008–2019: a retrospective nationwide study, <i>Heikki Ilmavirta</i> d. Increase in extensively-drug resistant <i>Shigella sonnei</i> infections in Spain, 2021-2022, <i>Camille Jacqueline</i> e. Failure of scabies treatment: a systematic review and meta-analysis, <i>Felix Reichert</i> f. International patient transfers causing healthcare associated outbreaks of carbapenem-resistant <i>Acinetobacter baumannii</i> in Germany, August – September 2021, <i>Jonatha Baum</i>
11.30-12.00	<p>Poster tour 13 moderated by TBC</p> <p>COVID-19: vaccine effectiveness</p> <ul style="list-style-type: none"> a. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children 5-11 years old in Italy (January -April 2022), <i>Chiara Sacco</i> b. Monitoring vaccine effectiveness against SARS-CoV-2 infection in a Dutch cohort – The VAccine Study COvid-19 (VASCO), <i>Anne Huijberts</i> c. Vaccine effectiveness of mRNA vaccines against COVID-19 hospitalisation during Omicron circulation in Europe in adults ≥ 20 years: I-MOVE-COVID-19 and ECDC hospital networks, 27 Dec 2021–31 Mar 2022, <i>Angela Mary C. Rose</i> d. Vaccine effectiveness of BNT162b2 COVID-19 in adolescents: results of a Portuguese population-based cohort study based on electronic health records linkage, <i>Baltazar Nunes</i> e. Relative effectiveness of COVID-19 vaccine booster dose against Delta and Omicron SARS-CoV-2 infection in a European healthcare worker cohort, June 2021- April 2022, <i>Camelia Savulescu</i> f. Effectiveness of BNT162b2 mRNA booster doses and hybrid-immunity against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN study September 2021 to February 2022, <i>Victoria Hall</i>